中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (23): 3400-3406.doi: 10.3969/j.issn.2095-4344.2016.23.008

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

PTEN基因沉默骨髓间充质干细胞移植治疗急性心肌梗死

徐慧敏,刘玉茹,万琪琳,李彦明,吴昌维   

  1. 河南大学淮河医院老年病科,河南省开封市  475000
  • 收稿日期:2016-04-20 出版日期:2016-06-03 发布日期:2016-06-03
  • 作者简介:徐慧敏,女,1980年生,河南省商水县人,汉族,2004年郑州大学医学院毕业,主治医师,主要从事老年心脑血管疾病方面的研究。

PTEN-silenced bone marrow mesenchymal stem cell transplantation for acute myocardial infarction

Xu Hui-min, Liu Yu-ru, Wan Qi-lin, Li Yan-ming, Wu Chang-wei   

  1. Department of Geriatrics, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China
  • Received:2016-04-20 Online:2016-06-03 Published:2016-06-03
  • About author:Xu Hui-min, Attending physician, Department of Geriatrics, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China

摘要:

文章快速阅读:

文题释义:
基因沉默:
双链RNA被特异的核酸酶降解,产生干扰小RNA(siRNA),这些siRNA与同源的靶RNA互补结合,特异性酶降解靶RNA,从而抑制、下调基因表达。
PTEN基因:是迄今发现的第一个具有特异性磷酸酶活性的抑癌基因,该基因的突变失活与人类多种恶性肿瘤的发生发展密切相关,在细胞的生长发育、信号转导和细胞凋亡中起着重要作用。

 

摘要
背景:
骨髓间充质干细胞移植治疗心肌梗死是近年来的研究热点,但是心肌梗死区域的缺血缺氧微环境和早期炎症反应不利于移植细胞的存活,影响治疗效果。
目的:探讨PTEN基因沉默骨髓间充质干细胞治疗急性心肌梗死的效果。
方法:①SD大鼠骨髓间充质干细胞随机分为3组,空白对照组不进行任何处理,阴性对照组用Lipofectamin2000转染无意义的NCsiRNA,RNAi组用Lipofectamin2000转染PTEN基因特异的siRNA。采用MTT法描绘细胞生长曲线,流式细胞仪检测细胞周期;②取30只SD大鼠建立心肌梗死模型,随机分为3组,每组10只,分别为空白对照组、阴性对照组、RNAi组。建模6 h后,使用微量注射器和立体定位仪在左心室前壁梗死区中心注射相应的骨髓间充质干细胞,治疗后4周进行超声心功能检测,采用荧光显微镜观察细胞的存活和增殖情况。
结果与结论:①RNAi组骨髓间充质干细胞在培养各时间点的吸光度值均显著大于空白对照组和阴性对照组;②RNAi组S+G2期细胞占总数的比例显著大于空白对照组和阴性对照组(P < 0.05);③RNAi组大鼠心肌组织中骨髓间充质细胞数量显著多于空白对照组和阴性对照组(P < 0.05);④治疗4周,RNAi组的左心室射血分数、左心室短轴缩短率显著小于空白对照组和阴性对照组(P < 0.05);⑤体外实验表明PTEN基因沉默能有效地促进骨髓间充质干细胞的增殖,抑制细胞凋亡;⑥体内实验表明PTEN基因沉默的骨髓间充质干细胞在心肌梗死区域更易存活和扩增,心功能改善明显。

 

关键词: 干细胞, 移植, 急性心肌梗死, 第10号染色体同源丢失性磷酸酶张力蛋白基因, 基因沉默, 骨髓间充质干细胞, 干细胞移植

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cell transplantation for myocardial infarction becomes popularized in recent years, but transplanted cells cannot survive and proliferate under early inflammatory reaction or local ischemia/hypoxia microenvironment, eventually hampering the therapeutic outcomes.
OBJECTIVE: To investigate the therapeutic effect of PTEN-silenced bone marrow mesenchymal stem cells on acute myocardial infarction.
METHODS: (1) Bone marrow mesenchymal stem cells from Sprague-Dawley rats were randomly assigned to receive no treatment, NCsiRNA transfection using Lipofectamin2000 or PTEN siRNA transfection using Lipofectamin2000. Cell growth curves were described using MTT method to detect cell cycle using flow cytometry. (2) Thirty Sprague-Dawley rats were selected to prepare myocardial infarction models that were randomized into three groups (n=10 per group): blank control, negative control and RNAi group. Six hours after modeling, bone marrow mesenchymal stem cells transfected with nothing, NCsiRNA and PTEN siRNA were respectively injected into the infarcted center of the left ventricular anterior wall in these three rat groups. After 4 weeks, all rats were subjected to cardiac function detection using echocardiography, and the survival and proliferation of bone marrow mesenchymal stem cells in the rats were observed by fluorescence microscopy.
RESULTS AND CONCLUSION: Compared with the other two groups, a significant increase in the absorbance values at different culture time, the proportion of cells in S+G2 phase, and the number of bone marrow mesenchymal stem cells in the myocardial tissue was found in the RNAi group (all P < 0.05). Additionally, the left ventricular ejection fraction and left ventricular shortening fraction were significantly reduced in the RNAi group than the blank control and negative control groups at 4 weeks after cell transplantation (P < 0.05). Both in vivo and in vitro experimental findings showed that PTEN silencing could effectively improve cell survival and proliferation in the infarcted myocardium. Moreover, in the in vivo experiment, an overt improvement in rat’s cardiac function was achieved. 

 

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

Key words: Myocardial Infarction, PTEN Phosphohydrolase, Bone Marrow, Mesenchymal Stem Cells, Gene Silencing, Tissue Engineering

中图分类号: